

Interaction Report**Report ID:****Date Produced:**

03 May 2025

Hepatology Treatment**Co-medications**

Bulevirtide

Levothyroxine

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Bulevirtide + Levothyroxine

Coadministration has not been studied. Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. As a precautionary measure, close clinical monitoring is warranted when NTCP substrates (e.g. thyroid hormones) are coadministered with bulevirtide. Where possible, coadministration of these substrates should be avoided.